| Bioactivity | TDP-43 degrader-1 (example 3) reduces the TDP-43 aggregation that can be in the research of Amyotrophic lateral sclerosis and? Alzheimer's disease[1]. | |||||||||
| Name | TDP-43 degrader-1 | |||||||||
| CAS | 2902692-25-3 | |||||||||
| Formula | C28H29N3O3 | |||||||||
| Molar Mass | 455.55 | |||||||||
| Appearance | 固体 | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
|||||||||
| Reference | [1]. Solas Dennis, et al. Preparation of substituted isoquinolines for the treatment of ALS. United States, US20230037538 A1 2023-02-09 |
TDP-43 degrader-1
CAS: 2902692-25-3 F: C28H29N3O3 W: 455.55
TDP-43 degrader-1 (example 3) reduces the TDP-43 aggregation that can be in the research of Amyotrophic lateral sclerosi
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.